More on Senesco’s Progress in their Cancer Therapy

“We think that it is significant because the starting dose in a first-in-humans study is chosen with safety as the priority. So seeing a tumor response is not necessarily expected. A response in just one patient needs to be kept in perspective. However we are pleased to see an effect and encouraged that higher doses might be even more effective.”